Amabiotics

Stellate Therapeutics (formerly Amabiotics) is a clinical-stage biotechnology company focused on developing first-in-class therapies for neurodegenerative diseases by leveraging the gut-brain axis. The company identifies and develops small molecule metabolites produced by the human microbiome that possess neuroprotective properties. Its lead candidate, ST-101 (formerly AMA-101), is being evaluated for its ability to slow the progression of Parkinson's disease by targeting alpha-synuclein pathology and providing neuroprotection. Stellate's approach combines metagenomics and metabolomics to discover endogenous molecules that can cross the blood-brain barrier and address unmet needs in neurology.